Menu Search
Equities

Biosynex SA

ALBIO:PAR

Biosynex SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)2.88
  • Today's Change-0.045 / -1.54%
  • Shares traded1.67k
  • 1 Year change-64.49%
  • Beta-2.5477
Data delayed at least 15 minutes, as of Nov 12 2024 14:43 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Biosynex SA's revenues fell -52.70% from 196.59m to 92.98m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 15.61m to a loss of 37.30m.
Gross margin24.67%
Net profit margin-37.18%
Operating margin-35.54%
Return on assets-16.08%
Return on equity-32.19%
Return on investment-27.57%
More ▼

Cash flow in EURView more

In 2023, cash reserves at Biosynex SA fell by 59.30m. Cash Flow from Financing totalled 5.17m or 5.56% of revenues. In addition the company used 9.65m for operations while cash used for investing totalled 54.81m.
Cash flow per share-2.50
Price/Cash flow per share--
Book value per share9.89
Tangible book value per share-1.39
More ▼

Growth rates in EUR

Year on year, growth in earnings per share excluding extraordinary items dropped -333.84%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		-8.45
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.